Lumosa Therapeutics Co., Ltd. (TPEX:6535)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
178.00
-11.00 (-5.82%)
Mar 31, 2025, 1:30 PM CST
0.23%
Market Cap 31.92B
Revenue (ttm) 39.15M
Net Income (ttm) -424.78M
Shares Out 168.90M
EPS (ttm) -2.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 594,913
Average Volume 297,575
Open 180.00
Previous Close 189.00
Day's Range 175.00 - 182.00
52-Week Range 163.50 - 400.00
Beta 0.42
RSI 24.58
Earnings Date Mar 4, 2025

About Lumosa Therapeutics

Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan, Asia, the Americas, and Europe. The company offers Naldebain (LT – 1001), an analgesic injection for severe pain relief after surgery. It is developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase I clinical trial for uremic pruritus; LT6001 that is in pre-clinical trials for neurological disorders; and LT2003, whic... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 43
Stock Exchange Taipei Exchange
Ticker Symbol 6535
Full Company Profile

Financial Performance

In 2024, Lumosa Therapeutics's revenue was 39.15 million, a decrease of -31.21% compared to the previous year's 56.92 million. Losses were -424.78 million, 78.4% more than in 2023.

Financial Statements

News

There is no news available yet.